CR20240312A - Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias - Google Patents

Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias

Info

Publication number
CR20240312A
CR20240312A CR20240312A CR20240312A CR20240312A CR 20240312 A CR20240312 A CR 20240312A CR 20240312 A CR20240312 A CR 20240312A CR 20240312 A CR20240312 A CR 20240312A CR 20240312 A CR20240312 A CR 20240312A
Authority
CR
Costa Rica
Prior art keywords
sup
macrocycles
imidazole
treatment
autoimmune disease
Prior art date
Application number
CR20240312A
Other languages
English (en)
Inventor
Jianguo Chen
Haixia Liu
Hong Shen
Zhenhong Zhang
Wolfgang Guba
Weixing Zhang
Yafei Liu
Jiansheng Zhu
Zhiwei Zhang
Wei Zhu
Shuai Chen
Xingchun Han
Min Jiang
Buyu Kou
Zhaohu Lin
Yao Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20240312A publication Critical patent/CR20240312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (Ia), (Ia), en donde R2 , M1 , M2 , M3 , Q1 y Q2 son como se describen en la presente, y las sales farmacéuticamente aceptables de estos, composiciones que incluyen los compuestos y métodos de uso de los compuestos.
CR20240312A 2022-02-02 2023-01-31 Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias CR20240312A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022075304 2022-02-02
CN2022137604 2022-12-08
PCT/EP2023/052218 WO2023148129A1 (en) 2022-02-02 2023-01-31 Imidazole macrocycles for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
CR20240312A true CR20240312A (es) 2024-09-04

Family

ID=85175764

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240312A CR20240312A (es) 2022-02-02 2023-01-31 Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias

Country Status (15)

Country Link
EP (1) EP4472739A1 (es)
JP (1) JP2025506393A (es)
KR (1) KR20240145483A (es)
CN (1) CN120641428A (es)
AR (1) AR128413A1 (es)
AU (1) AU2023215702A1 (es)
CA (1) CA3250448A1 (es)
CL (1) CL2024002334A1 (es)
CO (1) CO2024011088A2 (es)
CR (1) CR20240312A (es)
IL (1) IL314136A (es)
MX (1) MX2024009404A (es)
PE (1) PE20241762A1 (es)
TW (1) TW202342483A (es)
WO (1) WO2023148129A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR133199A1 (es) * 2023-07-10 2025-09-03 Hoffmann La Roche Macrociclos bicíclicos para el tratamiento de enfermedades autoinmunitarias
AR133266A1 (es) * 2023-07-19 2025-09-10 Hoffmann La Roche Macrociclos para el tratamiento de enfermedades autoinmunitarias
CN121532398A (zh) * 2023-07-21 2026-02-13 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的大环
AR133915A1 (es) 2023-09-26 2025-11-12 Hoffmann La Roche Macrociclos para el tratamiento de enfermedades autoinmunitarias
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220936T1 (hr) * 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterociklički amidi korisni kao modulatori proteina
WO2019053617A1 (en) * 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS

Also Published As

Publication number Publication date
EP4472739A1 (en) 2024-12-11
MX2024009404A (es) 2024-08-14
TW202342483A (zh) 2023-11-01
PE20241762A1 (es) 2024-08-28
CN120641428A (zh) 2025-09-12
IL314136A (en) 2024-09-01
WO2023148129A1 (en) 2023-08-10
KR20240145483A (ko) 2024-10-07
JP2025506393A (ja) 2025-03-11
AU2023215702A1 (en) 2024-07-25
AR128413A1 (es) 2024-05-08
CL2024002334A1 (es) 2025-01-17
CA3250448A1 (en) 2023-08-10
CO2024011088A2 (es) 2024-08-30

Similar Documents

Publication Publication Date Title
CR20240312A (es) Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
CR20250329A (es) Compuestos tricíclicos para el tratamiento del cáncer
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
EP4299135A3 (en) Benzisoxazole sulfonamide derivatives
EP4566612A3 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2026000537A (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
MX2025008327A (es) Composiciones y metodos para el tratamiento de trastornos del snc
MX2026001061A (es) Inhibidores de la fosfatidilinositol 3-cinasa (pi3k)
WO2011027249A3 (en) Benzimidazole derivatives
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MX2024003738A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MX2023015139A (es) Inhibidores de mutacion de her2.
MX2024002409A (es) Terapias contra el cancer.
MX2025000174A (es) Compuestos y metodos terapeuticos.
MX2025002166A (es) Compuestos y metodos para modular her2
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
MX2025000635A (es) Compuestos cíclicos y métodos de utilización de estos